Ressources Scientifiques

[EN] How to Better Optimize an Oncology Drug Discovery Program
Watch this oncology webinar on preclinical pharmacology, covering all step of the drug discovery journey from target validation to clinical studies...

Scientific Posters | AACR 2022
Find all 4 posters that are presented during AACR 2022. They unveil our expertise in oncology using our scientific know-how (medicinal chemistry, radio-imaging, in vivo model and microbiome)
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance [EN]
A lire dans Communication Biologics (Nature), les données du programme préclinique exoSTING, auquel Oncodesign a participé (Hepa1-6).
Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity [EN)
A lire dans Science Advances : le programme de développement préclinique d'exoASO-STAT6, un nouveau candidat de médecine de précision à base d'exosomes pour le traitement des tumeurs riches en macrophages.
OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients
Early/ late resistance marker; Immunological profile; NGS; Non small-cell lung cancer; Pancreatic ductal adenocarcinoma; Triple negative breast or Luminal Breast Cancer.
Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections
SARS-CoV-2; antiviral drug combination; hepatitis C virus; hepatitis E virus; human immunodeficiency virus; influenza A virus; interferon-alpha.

[EN] Preclinical Models for Microbiome Research in Oncology and Inflammatory Diseases
Learn how current in vivo preclinical models meet the needs of microbiome research and innovation while outlining their limitations and the challenges still to be overcome in this growing field.

[EN] How Rodent and NHP Models Support COVID-19 Treatment Development
Learn how to select the most appropriate COVID-19 animal model for preclinical studies in this webinar

[EN] Establishing an Expert Network for Your Radiopharmaceutical Drug Development Program
Learn how the DRIVE-MRT solution enables the rationalization, design & optimization of targeted & effective radiopharmaceuticals against specific cancers.
Structure-Based Design of small macrocyclic CDK9 degraders as chemical biology tools and beyond
With small macrocyclic “probes” from our proprietary library in the low nanomolar range IC50, we turned our attention to CDK9 inhibitors with good selectivity profile against CDK1/2/5/7 as a starting point for building bifunctional small macrocyclic kinase degraders.